CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA)

Annals of Oncology

Volumn 12, Issue 2, 2001, Pages 221-226

  Hanke, B ^a   Riedel, C ^b   Lampert, S ^b   Happich, K ^b   Martus, P ^c   Parsch, H ^b   Himmler, B ^c   Hohenberger, W ^b   Hahn, E G ^b   Wein, A ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

CA 19 9; CEA; Colorectal cancer; Palliative chemotherapy; Weekly 24 hour infusion of high dose 5 fluorouracil (5 FU) and folinic acid (FA)

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DIAGNOSTIC ACCURACY; DRUG INFUSION; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METASTASIS; PARAMETER; PATIENT MONITORING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PALLIATIVE CARE; RECURRENCE; SENSITIVITY AND SPECIFICITY;

EID: 0035104009     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008378412533     Document Type: Article

References (32)

1. Effective biomodulation by leukovorin of high-dose infusion fluorouracil given as weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
2. High efficacy of first-line 5-fluorouracil 24-hour infusion and folinic acid chemotherapy in patients with metastatic colorectal cancer
3. Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in previously untreated patients with metastatic colorectal carcinoma
4. A randomized phase III study comparing weekly folinic acid (FA) and high-dose 5-fluorouracil (5-FU) with monthly 5-FU/FA (days 1-5) in untreated patients with metastatic colorectal cancer
5. Verbesserungen der palliativen Behandlng des kolorektalen Karzinoms
6. Carcinoembryonic antigen: A human tumor marker, functions as an intercellular adhesion molecule
7. Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in dissiminated colorectal cancer
8. Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer
9. Long-term follow-up of colorectal carcinoma patients by repeated CEA radioimmuno-assay
10. Carcinoembryonic antigen
11. The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer
12. The use of tumor markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer
13. A multicenter phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal cancer
14. Evaluation of carcinoembryonic antigen (CEA) levels during CPT-11 treatment of patients with previously treated colorectal cancer
15. CEA monitoring of palliative treatment for colorectal carcinoma
16. Value of CEA determination in follow-up of patients with liver metastasis of colorectal cancers with loco-regional chemotherapy
17. Identification of gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin
18. Use of CA 19-9 in the early detection of recurrences in colorectal cancer: Comparison with CEA
19. Elevated CA 19-9 as the most significant prognostic factor in advanced colorectal cancer
20. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer
21. Carcinoembryonic antigen (CEA), alpha-fetoprotein, CA 19-9 and CA 125 in advanced colorectal cancer (ACC)
22. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continous infusion in pretreated metastatic colorectal cancer
23. Phase III study of irinotecan as second line chemotherapy in metastatic colorectal cancer
24. Phase II-study of 24-hour infusion with 5-fluorouracil (5-FU) and simultaneous sodium folinic acid in the first-line treatment of advanced colorectal cancer: Interim analysis
25. Measuring the accuracy of diagnostic systems
26. The clinical relevance of tumor marker CEA, CA 19-9 in regional chemotherapy of hepatic metastases of colorectal carcinoma
27. Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis
28. Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA
29. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer
30. Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma
31. Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer